Istituto Giannina Gaslini, Genoa, Italy.
Istituto Giannina Gaslini and Università degli Studi di Genova, Genoa, Italy.
Arthritis Rheumatol. 2016 Jun;68(6):1540-50. doi: 10.1002/art.39583.
To estimate the placebo effect in juvenile idiopathic arthritis (JIA) through a meta-analysis of phase III clinical trials with placebo comparator.
A systematic literature search was carried out up to December 2014. For parallel design studies the outcome was evaluated as a single 1-dimensional (1-D) variable or as a composite score; outcomes of withdrawal studies were evaluated only as composite scores.
We included 26 of 224 trials (12%). In trials with parallel study design and a 1-D outcome, the placebo effect was 0.35 (95% confidence interval [95% CI] 0.27-0.43). Among trials with parallel study design and a composite score outcome, the placebo rate response was higher in trials that included patients with nonsystemic JIA (0.35 [95% CI 0.29-0.42]) than in trials that included only patients with systemic JIA (0.17 [95% CI 0.10-0.30]). In the withdrawal design trials, the percentages of patients receiving placebo who had disease flares during the double-blind phase were lower in trials that included patients with nonsystemic JIA (0.55 [95% CI 0.47-0.64]) than in trials that included only patients with systemic JIA (0.68 [95% CI 0.33-0.90]).
In trials with a parallel study design a sizable number of patients seem to benefit from a placebo effect, although this effect is smaller in patients with systemic JIA. In trials with a withdrawal design the inverse placebo effect is similar among the different JIA categories. This placebo effect should be considered when evaluating the effectiveness of proposed interventions and for future calculations of sample size.
通过对安慰剂对照的 III 期临床试验进行荟萃分析,评估青少年特发性关节炎(JIA)的安慰剂效应。
系统检索截至 2014 年 12 月的文献。对于平行设计研究,结果评估为单一 1 维(1-D)变量或综合评分;撤退研究的结果仅评估为综合评分。
我们纳入了 224 项试验中的 26 项(12%)。在具有平行研究设计和 1-D 结局的试验中,安慰剂效应为 0.35(95%置信区间[95%CI]0.27-0.43)。在具有平行研究设计和综合评分结局的试验中,纳入非系统性 JIA 患者的试验中安慰剂反应率较高(0.35 [95%CI 0.29-0.42]),而仅纳入系统性 JIA 患者的试验中安慰剂反应率较低(0.17 [95%CI 0.10-0.30])。在撤退设计试验中,纳入非系统性 JIA 患者的试验中,在双盲期出现疾病发作的接受安慰剂治疗的患者比例较低(0.55 [95%CI 0.47-0.64]),而纳入仅系统性 JIA 患者的试验中该比例较高(0.68 [95%CI 0.33-0.90])。
在具有平行研究设计的试验中,尽管在系统性 JIA 患者中该效应较小,但似乎有相当数量的患者受益于安慰剂效应。在具有撤退设计的试验中,不同 JIA 类别之间的反向安慰剂效应相似。在评估拟议干预措施的有效性和未来计算样本量时,应考虑这种安慰剂效应。